Harmony Biosciences Holdings, Inc.

HRMY Healthcare Biotechnology

Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024.

Revenue
+12.3%
EPS
−6.24%
Free cash flow
−29.4%
Total debt
−11.5%

Quarter to September 2026, against a year earlier

33.04 0.57 +1.76%
Market cap
$1.9B
P/E
10.7×
Fwd P/E
9.9×
Dividend yield
—
F-score
5/9
Altman Z
5.23
Beneish M
−2.99
Dividend safety
n/a

Harmony Biosciences Holdings, Inc. (HRMY) Total debt

Alert me on Total debt

Harmony Biosciences Holdings, Inc.'s total debt at the end of fiscal 2025 was $163.7M, down 8.70% from $179.3M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $149.1M. Over the past ten years it has ranged from $97.9M (fiscal 2019) to $324.2M (fiscal 2018); the current reading is higher than 25% of that period. Harmony Biosciences Holdings, Inc. ranks 69th of 569 Biotechnology companies by total debt.

Total debt, annual

Embed this chart

Annual newest first

Period Total debt Change
FY2025 $163.7M (8.70%)
FY2024 $179.3M (7.39%)
FY2023 $193.6M 1.00%
FY2022 $191.6M (0.18%)
FY2021 $192.0M (1.17%)
FY2020 $194.3M 98.32%
FY2019 $97.9M (69.79%)
FY2018 $324.2M —

Quarterly newest first

Period Total debt Change
Sep 2026 $149.1M (3.15%)
Jun 2026 $154.0M (3.06%)
Mar 2026 $158.8M (2.96%)
Dec 2025 $163.7M (2.87%)
24 more quarters

Against its own ten years

Low $97.9M High $324.2M
Ten-year median $191.8M
Current reading's percentile 25

Total debt against peers

What Total debt is

Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.

Long Term Debt (Total) + Current Part of Debt

The full definition of Total debt →

More on HRMY